실시간 바이오 인텔리전스 · ADC · CGT

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

9,268+프로그램
35+FDA 승인
4,079+모집 중
ADC 1068·Antibody 5456·CGT 2744차세대 추천 →·Data Tier →
9268프로그램35FDA 승인
0오늘 방문
572누적 방문
8122갱신 대기S–CData TierS/A/B차세대1068HER2 breast5456Antibody2744CGT→Psoriasis→NSCLC35FDA 승인
피드Data Tier차세대

추천 비교

비교 도구 →
HER2 ADCEnhertu · Kadcyla · RC48CD19 CAR-TYescarta · KymriahPD-1Keytruda · Opdivo다발골수종Darzalex · BlenrepTROP2 ADCTrodelvy · Dato-DXd · SGNectin-4 · TROP2Padcev · Trodelvy건선 IL pathwayStelara · Cosentyx · SkyriziAnti-VEGF (안과)Eylea · LucentisAnti-TNFHumira · EnbrelIL-12/23Stelara · Skyrizi아토피·IL-13Dupixent · Ebglyss혈우병 유전자치료Hemgenix · Roctavian겸상적혈구 CGTCasgevy · Lyfgenia망막·DMD 유전자치료Luxturna · Elevidys

최근 활동

RSS →

빠른 검색 · 이슈 태그

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 4,162개
다음 갱신 D-12 · 마지막 7월 13일
AntibodystaleNeovii BiotechPhase 2

Catumaxomab (Catumaxomab)

Gastric Cancer; Gastric Adenocarcinoma · Gastric Cancer

#GastricCancer#Antibody#Phase2#항체#면역항체+3
임상시험 18상태 ACTIVE
AntibodystaleMerck Sharp & Dohme LLCPhase 2

Favezelimab (Favezelimab)

Neoplasm Metastasis · Neoplasms

#Neoplasms#Antibody#Phase2#항체#면역항체+3
효능 ORR 6.8%임상시험 18상태 DISCONTINUED
AntibodystaleBristol-Myers SquibbPhase 2

Urelumab (Urelumab)

Pancreatic Cancer · Malignant Tumors

#MalignantTumors#Antibody#Phase2#항체#면역항체+3
효능 ORR 5%임상시험 18상태 RECRUITING
ADCBiologicstaleFondazione per la Medicina Pers…Phase 3

Pralsetinib (Pralsetinib)

Breast Cancer; Gastrointestinal Cancer · Solid Tumor

#SolidTumor#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 53.8%임상시험 18상태 ACTIVE
AntibodystaleMerckPhase 2

pembrolizumab (Keytruda, Favezelimab/Pembrolizumab)

Neoplasm Metastasis · Neoplasms

#Neoplasms#Antibody#Phase2#항체#면역항체+3
효능 ORR 6.8%임상시험 18상태 ACTIVE
AntibodystaleRochePhase 1

Bevacizumab-IRDye800CW (Bevacizumab-IRDye800CW)

Adenomatous Polyposis Coli · Esophageal Cancer

#EsophagealCancer#Antibody#Phase1#항체#면역항체+3
임상시험 18상태 ACTIVE
AntibodystaleRegeneron PharmaceuticalsPhase 3

Odronextamab (Odronextamab)

Relapsed/Refractory Aggressive B-Cell Lymphoma · B-cell Non Hodgkin Lymphoma

#B-cellNonHodgkinLymphoma#Antibody#Phase3#항체#면역항체+4
임상시험 18상태 RECRUITING
ADCBiologicstaleShanghai JMT-Bio Inc.Phase 2

KN026 (KN026)

HER2-positive Colorectal Cancer; HER2-positive Biliary Tract Cancer · Advanced Breast Cancer

#AdvancedBreastCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 17상태 RECRUITING
ADCBiologicstaleGenentech, Inc.Phase 1

GDC-0941 (GDC-0941)

Metastatic Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1
임상시험 17상태 ACTIVE
ADCBiologicstaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin Tislelizumab)

Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 17상태 ACTIVE
AntibodystaleRochePhase 3

zanubrutinib, rituximab and lenalidomide (zanubrutinib, rituximab and lenalidomide)

Diffuse Large B-Cell Lymphoma · Diffuse Large B-Cell Lymphoma

#DiffuseLargeB-CellLymphoma#Antibody#Phase3#항체#면역항체+2
효능 ORR 45.7%임상시험 17상태 RECRUITING
AntibodystaleKite, A Gilead CompanyPhase 1

Utomilumab (Utomilumab)

Relapsed/Refractory Large B-cell Lymphoma · HER2

#HER2#Antibody#Phase1#항체#면역항체+4
효능 ORR 67%임상시험 17상태 ACTIVE
ADCBiologicstaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin combined with Toripalimab)

Paget Disease, Extramammary; Scrotum Disease · Paget Disease, Extramammary

#PagetDiseaseExtramammary#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+4
임상시험 17상태 RECRUITING
ADCBiologicstaleShanghai Henlius BiotechPhase 2

HLX43 (HLX43)

Advanced/Metastatic Malignant Solid Tumors · Hormone Receptor Positive HER-2 Negative

#HormoneReceptorPositiveHER-2Nega#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 17상태 RECRUITING
ADCBiologicstaleRemeGenApproved

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin combined with Tislelizumab)

Breast Cancer; Neoadjuvant Therapy · Breast Cancer

#BreastCancer#ADC#Approved#항체약물접합체#antibody-drug-conjugate+2
임상시험 17상태 ACTIVE
ADCBiologicstaleDanish Breast Cancer Cooperativ…Phase 3

Abemaciclib with ET (Abemaciclib with ET)

Metastatic Breast Cancer; ER-positive Breast Cancer · HER2

#HER2#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 0%임상시험 17상태 DISCONTINUED
ADCBiologicstaleEli Lilly and CompanyPhase 3

MIRV (MIRV)

Ovarian Neoplasms; Fallopian Tube Neoplasms · Ovarian Neoplasms

#OvarianNeoplasms#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 51.9%임상시험 17상태 RECRUITING
ADCBiologicstaleDaiichi SankyoPhase 3

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, T-Dxd + Pertuzumab)

HER2 + Breast Cancer · HER2

#HER2#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 1%임상시험 17상태 RECRUITING
ADCBiologicstaleMabwell (Shanghai) Bioscience C…Phase 3

9MW2821 (9MW2821)

Locally Advanced or Metastatic Triple-negative Breast Cancer · HER2

#HER2#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
임상시험 17상태 RECRUITING
AntibodystaleAmgenPhase 2

Panitumumab + paclitaxel (Panitumumab + paclitaxel)

Head and Neck Cancer · Head and Neck Cancer

#HeadandNeckCancer#Antibody#Phase2#항체#면역항체+2
효능 ORR 77.3%임상시험 17상태 ACTIVE
ADCBiologicstaleBeiGenePhase 2

disitamab vedotin (Disitamab Vedotin, RC48, tislelizumab+disitamab-vedotin)

Neoadjuvant Immunotherapy · Neoadjuvant Immunotherapy

#NeoadjuvantImmunotherapy#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 17상태 RECRUITING
ADCBiologicstaleSuzhou Suncadia Biopharmaceutic…Phase 2

SHR-A1921 (SHR-A1921)

Advanced Breast Cancer; Metastatic Breast Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 17상태 RECRUITING
CGTBiologicstaleStephan Grupp MD PhDPhase 1

BEAM-201 (Allogeneic anti-CD7 CAR-T cells, Allogeneic anti-CD7 CAR-T cells (BEAM-201))

T-Cell Acute Lymphoblastic Leukemia/Lymphoma · T-Cell Acute Lymphoblastic Leukemia/Lymp

#T-CellAcuteLymphoblasticLeukemia#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 16상태 RECRUITING
CGTBiologicstaleDutch Cancer SocietyPhase 1

UCB-NK cells (UCB-NK cells)

Recurrent Ovarian Carcinoma; Recurrent Fallopian Tube Carcinoma · Recurrent Ovarian Carcinoma

#RecurrentOvarianCarcinoma#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 16상태 ACTIVE
AntibodystaleRochePhase 2

90Yttrium-Ibritumomab Tiuxetan (Zevalin®, 90Yttrium-Ibritumomab Tiuxetan, 90Yttrium-Ibritumomab Tiuxetan (Zevalin®)+Rituximab)

Follicular Lymphoma · Follicular Lymphoma

#FollicularLymphoma#Antibody#Phase2#항체#면역항체+2
효능 ORR 89%임상시험 16상태 ACTIVE

33 / 167 페이지

← 이전다음 →
전체 9,268개 프로그램 보기